Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KPTI Stock Forecast 2026-2027
$9.50
Current Price
$215.30M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to KPTI Price Targets
+68.4%
To High Target of $16.00
+52.6%
To Median Target of $14.50
-26.3%
To Low Target of $7.00
KPTI Price Momentum
+11.8%
1 Week Change
+23.9%
1 Month Change
+116.4%
1 Year Change
+29.1%
Year-to-Date Change
-13.6%
From 52W High of $10.99
+160.3%
From 52W Low of $3.65
📊 TOP ANALYST CALLS
Did KPTI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Karyopharm is one of their latest high-conviction picks.
Latest KPTI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, KPTI has a bullish consensus with a median price target of $14.50 (ranging from $7.00 to $16.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $9.50, the median forecast implies a 52.6% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KPTI Analyst Ratings
6
Buy
1
Hold
0
Sell
KPTI Price Target Range
Low
$7.00
Average
$14.50
High
$16.00
Current: $9.50
Latest KPTI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KPTI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $13.00 |
| Apr 27, 2026 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Mar 30, 2026 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Mar 25, 2026 | Baird | Outperform | Maintains | $N/A | |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 10, 2026 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Feb 18, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 5, 2026 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 4, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Oct 13, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Oct 9, 2025 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Oct 9, 2025 | Baird | Outperform | Maintains | $N/A | |
| Aug 12, 2025 | Baird | Outperform | Maintains | $N/A | |
| Jul 16, 2025 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Jul 11, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Assumes | $27.00 |
| May 13, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| May 13, 2025 | Barclays | Overweight | Maintains | $N/A | |
| May 13, 2025 | Baird | Outperform | Maintains | $N/A | |
| Mar 3, 2025 | Baird | Outperform | Maintains | $N/A | |
| Feb 26, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Karyopharm Therapeutics Inc. (KPTI) Competitors
The following stocks are similar to Karyopharm based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Karyopharm Therapeutics Inc. (KPTI) Financial Data
Karyopharm Therapeutics Inc. has a market capitalization of $215.30M with a P/E ratio of -0.5x. The company generates $151.12M in trailing twelve-month revenue with a -129.0% profit margin.
Revenue growth is +16.8% quarter-over-quarter, while maintaining an operating margin of -76.3% and return on equity of +66.9%.
Valuation Metrics
Market Cap
$215.30M
Enterprise Value
$420.04M
P/E Ratio
-0.5x
PEG Ratio
0.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+16.8%
Gross Margin
+96.2%
Operating Margin
-76.3%
Net Margin
-129.0%
EPS Growth
+16.8%
Financial Health
Cash/Price Ratio
+42.4%
Current Ratio
1.1x
Debt/Equity
-1.1x
ROE
+66.9%
ROA
-40.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Karyopharm Therapeutics Inc. (KPTI) Business Model
About Karyopharm Therapeutics Inc.
What They Do
Develops innovative cancer therapies.
Business Model
The company operates as a commercial-stage biopharmaceutical firm, focusing on the discovery, development, and commercialization of cancer therapies. It generates revenue primarily through the sale of its lead product, XPOVIO, which is approved for treating various hematologic malignancies in the U.S. market.
Additional Information
Karyopharm Therapeutics is headquartered in Newton, Massachusetts, and emphasizes advancing cancer treatment options using its unique approach targeting nuclear export mechanisms.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
228
CEO
Mr. Richard A. Paulson M.B.A.
Country
United States
IPO Year
2013
Website
www.karyopharm.comKaryopharm Therapeutics Inc. (KPTI) Latest News & Analysis
Latest News
Quick Summary
Karyopharm Therapeutics Inc. (KPTI) shared results from the Phase III SENTRY trial, evaluating Selinexor combined with Ruxolitinib for treating Myelofibrosis.
Why It Matters
The Phase III trial results for Karyopharm's drug could impact stock prices, investor confidence, and future funding or partnerships, signaling potential market opportunities or risks in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Karyopharm Therapeutics will present data from the SENTRY Trial at the EHA Congress, indicating that SVR35 with Selinexor plus Ruxolitinib may predict overall survival.
Why It Matters
The announcement of promising data from the SENTRY Trial and its recognition at a major conference could boost Karyopharm Therapeutics' stock, signaling potential market interest and investment opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Karyopharm Therapeutics reported that Selinexor combined with Ruxolitinib nearly doubled the SVR35 response rate at 24 weeks in a Phase 3 trial for myelofibrosis, showing promising survival benefits.
Why It Matters
Positive trial results for Karyopharm's Selinexor with Ruxolitinib suggest significant efficacy in treating myelofibrosis, potentially boosting the company's stock and attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
12 days ago
Quick Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in a virtual fireside chat hosted by Cantor on June 8, 2026, at 12:00 p.m.
Why It Matters
Karyopharm's participation in a fireside chat may highlight its strategic direction and updates on cancer therapies, influencing investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A conference call featuring Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial, is scheduled for June 2, 2026, at 2:00 p.m. ET in Newton, Mass.
Why It Matters
The conference call with Dr. Mascarenhas may provide critical updates on the Phase 3 SENTRY Trial, influencing investor sentiment and stock performance related to the trial's outcomes.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Karyopharm Therapeutics granted 1,200 restricted stock units to a new employee, indicating potential growth and recruitment efforts in their cancer therapy sector.
Why It Matters
The granting of RSUs indicates Karyopharm is investing in talent, which may enhance innovation and growth, potentially boosting future stock performance and company valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KPTI Stock
What is Karyopharm Therapeutics Inc.'s (KPTI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Karyopharm Therapeutics Inc. (KPTI) has a median price target of $14.50. The highest price target is $16.00 and the lowest is $7.00.
Is KPTI stock a good investment in 2026?
According to current analyst ratings, KPTI has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KPTI stock?
Wall Street analysts predict KPTI stock could reach $14.50 in the next 12 months. This represents a 52.6% increase from the current price of $9.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Karyopharm Therapeutics Inc.'s business model?
The company operates as a commercial-stage biopharmaceutical firm, focusing on the discovery, development, and commercialization of cancer therapies. It generates revenue primarily through the sale of its lead product, XPOVIO, which is approved for treating various hematologic malignancies in the U.S. market.
What is the highest forecasted price for KPTI Karyopharm Therapeutics Inc.?
The highest price target for KPTI is $16.00 from at , which represents a 68.4% increase from the current price of $9.50.
What is the lowest forecasted price for KPTI Karyopharm Therapeutics Inc.?
The lowest price target for KPTI is $7.00 from at , which represents a -26.3% decrease from the current price of $9.50.
What is the overall KPTI consensus from analysts for Karyopharm Therapeutics Inc.?
The overall analyst consensus for KPTI is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are KPTI stock price projections?
Stock price projections, including those for Karyopharm Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 11:52 AM UTC